Search research articles
Contact Us
Filters
Showing results (251-260 of 298) with videos related to
Page
of 30
Sort By:
Ejhaem
|
December 18, 2024
Association between microenvironment-related genes and prognosis of primary central nervous system lymphoma
Keiichiro Hattori, Kenichi Makishima, Sakurako Suma, et al.
Acta Neuropathologica Communications
|
September 25, 2023
Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study
Kohei Fukuoka, Jun Kurihara, Tomoko Shofuda, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
October 23, 2023
Inflammatory Rhabdomyoblastic Tumor: Clinicopathologic and Molecular Analysis of 13 Cases
Toru Odate, Kaishi Satomi, Takashi Kubo, et al.
Scientific Reports
|
August 8, 2018
Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas
Hideyuki Arita, Manabu Kinoshita, Atsushi Kawaguchi, et al.
Neuro-Oncology
|
June 20, 2022
The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas
Atsushi Natsume, Yoshiki Arakawa, Yoshitaka Narita, et al.
Acta Neuropathologica
|
August 31, 2017
Distinct molecular profile of diffuse cerebellar gliomas
Masashi Nomura, Akitake Mukasa, Genta Nagae, et al.
Acta Neuropathologica
|
June 20, 2021
TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma
Kenji Fujimoto, Hideyuki Arita, Kaishi Satomi, et al.
DEN Open
|
February 6, 2023
Local recurrence of submucosal invasive colorectal cancer after endoscopic submucosal dissection revealed by copy number variation
Yu Okazawa, Kiichi Sugimoto, Yuki Ii, et al.
Cancers
|
November 26, 2022
Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study
Motoo Nagane, Koichi Ichimura, Ritsuko Onuki, et al.
Scientific Reports
|
September 21, 2023
Distinct patterns of copy number alterations may predict poor outcome in central nervous system germ cell tumors
Hirokazu Takami, Kaishi Satomi, Kohei Fukuoka, et al.
Page
of 30
Search research articles
Search
Showing results (251-260 of 298) with videos related to
Sort By:
Page
of 30
Ejhaem
|
December 18, 2024
Association between microenvironment-related genes and prognosis of primary central nervous system lymphoma
Keiichiro Hattori, Kenichi Makishima, Sakurako Suma, et al.
Acta Neuropathologica Communications
|
September 25, 2023
Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study
Kohei Fukuoka, Jun Kurihara, Tomoko Shofuda, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
October 23, 2023
Inflammatory Rhabdomyoblastic Tumor: Clinicopathologic and Molecular Analysis of 13 Cases
Toru Odate, Kaishi Satomi, Takashi Kubo, et al.
Scientific Reports
|
August 8, 2018
Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas
Hideyuki Arita, Manabu Kinoshita, Atsushi Kawaguchi, et al.
Neuro-Oncology
|
June 20, 2022
The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas
Atsushi Natsume, Yoshiki Arakawa, Yoshitaka Narita, et al.
Acta Neuropathologica
|
August 31, 2017
Distinct molecular profile of diffuse cerebellar gliomas
Masashi Nomura, Akitake Mukasa, Genta Nagae, et al.
Acta Neuropathologica
|
June 20, 2021
TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma
Kenji Fujimoto, Hideyuki Arita, Kaishi Satomi, et al.
DEN Open
|
February 6, 2023
Local recurrence of submucosal invasive colorectal cancer after endoscopic submucosal dissection revealed by copy number variation
Yu Okazawa, Kiichi Sugimoto, Yuki Ii, et al.
Cancers
|
November 26, 2022
Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study
Motoo Nagane, Koichi Ichimura, Ritsuko Onuki, et al.
Scientific Reports
|
September 21, 2023
Distinct patterns of copy number alterations may predict poor outcome in central nervous system germ cell tumors
Hirokazu Takami, Kaishi Satomi, Kohei Fukuoka, et al.
Page
of 30